0 740

Cited 0 times in

Cancer development in Korean patients with ANCA-associated vasculitis: a single centre study

DC Field Value Language
dc.contributor.author박용범-
dc.contributor.author송정식-
dc.contributor.author안성수-
dc.contributor.author유주영-
dc.contributor.author이상원-
dc.contributor.author정승민-
dc.date.accessioned2018-08-28T17:17:47Z-
dc.date.available2018-08-28T17:17:47Z-
dc.date.issued2018-
dc.identifier.issn0392-856X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162456-
dc.description.abstractOBJECTIVES: We investigated the incidence rate and type of cancer, and furthermore, estimated the standardised incidence ratios (SIRs) of cancer in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Korea. METHODS: We retrospectively included 150 patients with AAV [81 patients with microscopic polyangiitis (MPA), 38 with granulomatosis with polyangiitis (GPA) and 31 patients with eosinophilic GPA (EGPA)], and reviewed their medical records. We collected demographic, clinical and laboratory data, and reviewed the use of glucocorticoid and immunosuppressive drugs administered until detection of cancer or last visit. We estimated the SIRs of cancer according to totality, gender, age, AAV variants and each type of cancer. RESULTS: The mean age at diagnosis of AAV was 55.2 years and that at last visit was 59.5 years. The mean follow-up duration was 50.7 months. Four of 150 AAV patients had cancer (2.7%), and they got four different types of cancers including gastric cancer, lung cancer, prostate cancer and Non-Hodgkin lymphoma. Two patients exhibited gap-time from AAV to malignancy less than one year, and the rest of them exhibited gap-time of 8 and 6 years, respectively. The overall SIR of cancer in AAV patients was 1.43 (95% confidence interval 0.391, 3.671). The SIRs of cancer based on gender, and age at cancer or last visit, AAV variants and each type of cancer were not significant, either. CONCLUSIONS: The risk of cancer is low in Korean patients with AAV.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherClinical And Experimental Rheumatology S.A.S-
dc.relation.isPartOfCLINICAL AND EXPERIMENTAL RHEUMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleCancer development in Korean patients with ANCA-associated vasculitis: a single centre study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorJuyoung Yoo-
dc.contributor.googleauthorSung Soo Ahn-
dc.contributor.googleauthorSeung Min Jung-
dc.contributor.googleauthorJason Jungsik Song-
dc.contributor.googleauthorYong-Beom Park-
dc.contributor.googleauthorSang-Won Lee-
dc.contributor.localIdA01579-
dc.contributor.localIdA02057-
dc.contributor.localIdA02233-
dc.contributor.localIdA05157-
dc.contributor.localIdA02824-
dc.contributor.localIdA05179-
dc.relation.journalcodeJ00555-
dc.identifier.eissn1593-098X-
dc.identifier.pmid29465366-
dc.identifier.urlhttp://www.clinexprheumatol.org/abstract.asp?a=12413-
dc.contributor.alternativeNamePark, Yong Beom-
dc.contributor.alternativeNameSong, Jung Sik-
dc.contributor.alternativeNameAhn, Sung Soo-
dc.contributor.alternativeNameYoo, Juyoung-
dc.contributor.alternativeNameLee, Sang Won-
dc.contributor.alternativeNameJung, SeungMin-
dc.contributor.affiliatedAuthorPark, Yong Beom-
dc.contributor.affiliatedAuthorSong, Jung Sik-
dc.contributor.affiliatedAuthorAhn, Sung Soo-
dc.contributor.affiliatedAuthorYoo, Juyoung-
dc.contributor.affiliatedAuthorLee, Sang Won-
dc.contributor.affiliatedAuthorJung, SeungMin-
dc.citation.volume36 Suppl 111-
dc.citation.number2-
dc.citation.startPage73-
dc.citation.endPage77-
dc.identifier.bibliographicCitationCLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Vol.36 Suppl 111(2) : 73-77, 2018-
dc.identifier.rimsid60038-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.